All-cause mortality significantly lower with GLP-1 RA use, with consistent benefit across major cancer types, most GLP-1 RA types.

The therapy shows efficacy in improving diarrhea, abdominal pain in GLP-1, GLP-1/GIP-treated patients with diabetes and/or ...

Among patients eligible for MBS, GLP-1 RA prescriptions increased from 2018 to 2025, while MBS use decreased beginning in 2023.

GLP-1 receptor agonist therapy for type 2 diabetes or obesity is associated with a significantly lower risk of developing ...

GLP-1 receptor agonists like semaglutide are being used off-label by healthy people hoping to slow ageing, despite limited ...

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing ...

Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

Taking GLP-1 RAs is associated with fewer hospitalizations overall and less need for medications used to stop and prevent ...

Dr McIntyre and colleagues share new insight on how GLP-1 receptor agonists may protect against lithium-induced kidney damage in patients treated for bipolar disorder.

A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 ...

Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy ...

GLP-1 receptor agonists appear to be associated with an increased risk for osteoporosis and other orthopedic conditions.